Next Article in Journal
Obesity Drug Update: The Lost Decade?
Next Article in Special Issue
GPCR Conformations: Implications for Rational Drug Design
Previous Article in Journal
Allosteric Modulation of αβδ GABAA Receptors
Previous Article in Special Issue
Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development
Pharmaceuticals 2010, 3(11), 3478-3493; doi:10.3390/ph3113478

Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease

 and *
Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, FL 32610, USA
* Author to whom correspondence should be addressed.
Received: 21 September 2010 / Revised: 27 October 2010 / Accepted: 8 November 2010 / Published: 9 November 2010
(This article belongs to the Special Issue GPCR Based Drug Discovery)
View Full-Text   |   Download PDF [307 KB, uploaded 9 November 2010]   |   Browse Figures


Patients with hypertension often manifest a dysregulated renin-angiotensin-aldosterone system (RAAS). Most of the available treatment approaches for hypertension are targeted towards the RAAS including direct renin inhibition, ACE inhibition, angiotensin II type 1 receptor (AT1-R) blockade, and aldosterone receptor antagonism. The Jak2 signaling pathway is intricately coupled to the AT1-R signaling processes involved in hypertension. Here, we review the involvement of Jak2 in the pathogenesis of hypertension, and its potential as a therapeutic target for treatment of AT1-R mediated cardiovascular disease. Jak2 may provide a rational therapeutic approach for patients whose blood pressure is not controlled by standard therapies.
Keywords: angiotensin II; Jak2; AT1-receptor; hypertension angiotensin II; Jak2; AT1-receptor; hypertension
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Kirabo, A.; Sayeski, P.P. Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. Pharmaceuticals 2010, 3, 3478-3493.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert